Turn Therapeutics Inc.
TTRX
$13.90
$1.249.80%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 33.73% | -3.88% | |||
| Gross Profit | -33.73% | 3.88% | |||
| SG&A Expenses | 1.43% | -47.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.50% | -35.93% | |||
| Operating Income | -31.50% | 35.93% | |||
| Income Before Tax | -502.44% | -447.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -502.44% | -447.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -502.44% | -447.90% | |||
| EBIT | -31.50% | 35.93% | |||
| EBITDA | -31.77% | 36.13% | |||
| EPS Basic | -496.96% | -435.71% | |||
| Normalized Basic EPS | -495.63% | -437.70% | |||
| EPS Diluted | -496.96% | -435.71% | |||
| Normalized Diluted EPS | -495.63% | -437.70% | |||
| Average Basic Shares Outstanding | 1.06% | 3.69% | |||
| Average Diluted Shares Outstanding | 1.06% | 3.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||